Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

<p>Supplementary Dataset S9</p>

Збережено в:

Бібліографічні деталі
Автор:	Cara Abecunas (14960274) (author)
Інші автори:	Christopher E. Whitehead (14960277) (author), Elizabeth K. Ziemke (14960280) (author), Douglas G. Baumann (14960283) (author), Christy L. Frankowski-McGregor (14960286) (author), Judith S. Sebolt-Leopold (14960289) (author), Mohammad Fallahi-Sichani (14960292) (author)
Опубліковано:	2025
Предмети:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Drug Targets Skin Cancers Melanoma Small Molecule Agents Kinase inhibitors Systems Biology
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Dataset S1 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S2 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S3 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S4 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S5 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S6 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S7 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Dataset S8 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
за авторством: Cara Abecunas (14960274)
Опубліковано: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
за авторством: James S. Wilmott (15008931)
Опубліковано: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
за авторством: James S. Wilmott (15008931)
Опубліковано: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
за авторством: Ossia M. Eichhoff (14964145)
Опубліковано: (2025)

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.
за авторством: Fengyi Mao (15073242)
Опубліковано: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
за авторством: Jitske van den Bulk (17142147)
Опубліковано: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
за авторством: Jitske van den Bulk (17142147)
Опубліковано: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
за авторством: Jitske van den Bulk (17142147)
Опубліковано: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
за авторством: Jitske van den Bulk (17142147)
Опубліковано: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
за авторством: Jitske van den Bulk (17142147)
Опубліковано: (2025)

Polo-like kinase 1 (PLK1) is involved in melanoma progression.
за авторством: Fengyi Mao (15073242)
Опубліковано: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.
за авторством: Fengyi Mao (15073242)
Опубліковано: (2025)

Supplementary Table 1 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
за авторством: Nneoma Adaku (16991063)
Опубліковано: (2025)

Supplementary Table 2 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
за авторством: Nneoma Adaku (16991063)
Опубліковано: (2025)

Supplementary Table 3 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
за авторством: Nneoma Adaku (16991063)
Опубліковано: (2025)

Overexpressed Polo-like kinase 1 (PLK1) promotes metastasis and metabolic reprogramming in melanoma.
за авторством: Fengyi Mao (15073242)
Опубліковано: (2025)

Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S7 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Table 3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
за авторством: Andrew W. Hahn (15024693)
Опубліковано: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
за авторством: Alexander N. Shoushtari (15023909)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_e3ng58o60bh7qqc16qh2psl7qf